Skip to main content

Advertisement

SpringerLink
Log in

How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), two drug classes that effectively block the actions of the renin-angiotensin system (RAS), have unique capabilities as antihypertensive agents. Recent landmark clinical trials have demonstrated their important roles as primary therapy for the prevention of renal disease in diabetes. The optimal dosage of these RAS blockers required to slow the progression of renal disease or impair the development of cardiovascular risk is not known. However, data from many studies strongly support the use of the higher doses of ACE inhibitors or ARBs to reduce proteinuria. All studies of kidney disease progression demonstrate benefit on slowing only when blood pressure is reduced when using higher doses. In order to accrue the optimum benefit from ACE inhibitors and ARBs, the dose-response relationship for diabetic renal disease will have to be determined. The best strategy, ie, supramaximal doses of ACE inhibitors or ARBs or combining them, is still a matter of debate but may be resolved soon by results of ongoing studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002, 39:S1–S246.

  2. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26:S80-S82.

    Article  PubMed  Google Scholar 

  3. Molitch ME, DeFronzo RA, Franz MJ, et al.: Diabetic nephropathy. Diabetes Care 2003, 26:S94-S98.

    Article  PubMed  Google Scholar 

  4. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–886. The first of the two large studies that accounted for an ARB recommendation in type 2 diabetes. In this study the superiority of irbesartan was shown compared with amlodipine.

    Article  PubMed  CAS  Google Scholar 

  5. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type diabetes and nephropathy. N Engl J Med 2001, 345:861–869. This study clearly disclosed the significant effect of the ARB (losartan) on preventing the progression to hard endpoints.

    Article  PubMed  CAS  Google Scholar 

  6. Heart Outcomes Prevention Evaluation (HOPE) Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.

    Article  Google Scholar 

  7. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. This study included two different doses of irbesartan for treatment of type 2 diabetics with proteinuria. The higher dose (300 mg) was more powerful toward favorable changes of proteinuric status.

    Article  PubMed  CAS  Google Scholar 

  8. Miettinen H, Haffner SM, Lehto S, et al.: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996, 27:2033–2039.

    PubMed  CAS  Google Scholar 

  9. Navis G, de Zeeuw D: Titrating for antiproteinuric effect: the clue to renoprotection?. J Hum Hypertens 1996, 10:669–673.

    PubMed  CAS  Google Scholar 

  10. De Jong PE, Navis G, de Zeeuw D: Renoprotective therapy: titration against urinary protein excretion. Lancet 1999, 354:352–353.

    Article  PubMed  Google Scholar 

  11. Peters H, Ritz E: Dosing angiotensin II blockers—beyond blood pressure. Nephrol Dial Transplant 1999, 14:2568–2570.

    Article  PubMed  CAS  Google Scholar 

  12. Weinberg MS, Cord R, Weinberg AJ, Zappe DH: The effect of high dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. J Renin Angiotensin Aldosterone Syst 2001, 2:S196-S198.

    CAS  Google Scholar 

  13. Bakris GL, Slataper R, Vicknair N, Sadler R: ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994, 8:2–6.

    Article  PubMed  CAS  Google Scholar 

  14. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003, 361:117–124.

    Article  PubMed  CAS  Google Scholar 

  15. Forclaz A, Maillard M, Nussberger J, et al.: Angiotensin II receptor blockade. Is there truly a benefit of adding an ACE Inhibitor? Hypertension 2003, 41:31–36.

    Article  PubMed  CAS  Google Scholar 

  16. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106:672–678.

    Article  PubMed  CAS  Google Scholar 

  17. Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382–2391.

    PubMed  CAS  Google Scholar 

  18. Ruggenenti P, Remuzzi G: The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes. Exp Nephrol 1996, 4:53–60.

    PubMed  CAS  Google Scholar 

  19. Hollenberg NK: AT(1)-receptor blockade and the kidney: importance of non-ACE pathways in health and disease. J Hum Hypertens 2002, 16:S59-S63.

    Article  PubMed  CAS  Google Scholar 

  20. Weinberg MS, Weinberg AJ, Zappe DH: Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 2000, 1:217–233.

    PubMed  CAS  Google Scholar 

  21. Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001, 37:477–483.

    Article  PubMed  CAS  Google Scholar 

  22. Buter H, Hemmelder MH, Navis G, et al.: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998, 13:1682–1685.

    Article  PubMed  CAS  Google Scholar 

  23. Laverman GD, Navis G, Henning RH, et al.: Dual reninangiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002, 62:1020–1025.

    Article  PubMed  CAS  Google Scholar 

  24. Haas M, Leko-Hohr Z, Erler C, Mayer G: Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002, 40:458–463.

    Article  PubMed  CAS  Google Scholar 

  25. Komine N, Khang S, Wead LM, et al.: Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002, 39:159–164.

    PubMed  CAS  Google Scholar 

  26. Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874–1880. This study evaluated the antiproteinuric effects of adding high-dose ARB therapy (irbesartan 300 mg/d) to pre-existing maximal ACE inhibitor therapy.

    Article  PubMed  CAS  Google Scholar 

  27. Kickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infacrction: the OPTIMAAL randomized trial. Lancet 2002, 360:752–760.

    Article  Google Scholar 

  28. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compated with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587.

    Article  PubMed  CAS  Google Scholar 

  29. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study(LIFE): a randomized trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  30. Lindholm LH, Ibsen H, Dahlof B, et al., for the LIFE study group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  31. Packer M, Poole-Wilson PA, Armstrong PW: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999, 100:2312–2318.

    PubMed  CAS  Google Scholar 

  32. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al.: High-versus low-dose ACE inhibition in chronic heart failure: a doubleblind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998, 32:1811–1818.

    Article  PubMed  Google Scholar 

  33. Cohn JN, Tognoni G, for the VALSARTAN Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  34. Pacher R, Stanek B, Globits S, et al.: Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Eur Heart J 1996, 17:1223–1232.

    PubMed  CAS  Google Scholar 

  35. Clement DL, De Buyzere M, Tomas M, Vanavermaete G: Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS). Acta Cardiol 2000, 55:1–7.

    Article  PubMed  CAS  Google Scholar 

  36. Luzier AB, Forrest A, Adelman M, et al.: Impact of angiotensinconverting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998, 82:465–469.

    Article  PubMed  CAS  Google Scholar 

  37. NETWORK Investigators: Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998, 19:481–489.

    Article  CAS  Google Scholar 

  38. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al.: Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol 2000, 36:2090–2095.

    Article  PubMed  CAS  Google Scholar 

  39. Dunselman PH for the Replacement of Angiotensin Converting Enzyme Inhibition (REPLACE) Investigators: Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol 2001, 77:131–138.

    Article  Google Scholar 

  40. Tang WH, Vagelos RH, Yee YG, et al.: Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002, 39:70–78.

    Article  PubMed  CAS  Google Scholar 

  41. Campbell DJ, Aggarwal A, Esler M, Kaye D: Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001, 358:1609–1610.

    Article  PubMed  CAS  Google Scholar 

  42. Lonn EM, Yusuf S, Dzavilk V, et al.: Effects of ramipril and vitamin E on atherosclerosis. The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001, 103:919–925.

    PubMed  CAS  Google Scholar 

  43. Reddy MS, Landa M, Stark PC, et al., Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Disease (AIPRD) Study Group: Antiproteinuric dose response of angiotensinconverting enzyme inhibitors in non-diabetic chronic kidney disease. J Am Soc Nephrol 2002, 13:264A.

    Google Scholar 

  44. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  45. Ravid M, Brosh D, Levi Z, et al.: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998, 128:982–988.

    PubMed  CAS  Google Scholar 

  46. O’Hare P, Bilbous R, Mitchell T: Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000, 23:1823–1829.

    Article  PubMed  CAS  Google Scholar 

  47. Okada T, Toshiyuki N, Matsumoto H, et al.: Renoprotective effect of combination with angiotensin converting enzyme inhibitor and angiotensin receptor blocker in diabetic nephropathy with renal failure. J Am Soc Nephrol 2002, 13:687A.

    Google Scholar 

  48. Andersen S, Tarnow L, Rossing P, et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601–606. This study compared the dose-related effects of ARB versus ACE inhibitor therapy on the reduction in albuminuria in patients with diabetic nephropathy.

    Article  PubMed  CAS  Google Scholar 

  49. Andersen S, Rossing P, Juhl TR, et al.: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002, 17:1413–1418. One of the few studies addressed the optimal dose of ARBs. In type 1 diabetes, 100 mg losartan was associated with the greatest renoprotection, the latter based on BP and proteinuria reduction.

    Article  PubMed  CAS  Google Scholar 

  50. Laverman GD, Steen Andersen, Peter Rossing, et al.: Dosedependent reduction of proteinuria by losartan does not require reduction of blood pressure. J Am Soc Nephrol 2002, 13:265A.

    Google Scholar 

  51. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003, 14:992–999.

    Article  PubMed  CAS  Google Scholar 

  52. Andersen NH, Mogensen CE: Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence and against the combination in the treatment of hypertension and proteinuria. Curr Hypertens Rep 2002, 4:394–402.

    PubMed  Google Scholar 

  53. Bos H, Andersen S, Rossing P, et al.: Role of patient factors therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 2000, 75:S32-S37.

    Article  CAS  Google Scholar 

  54. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000, 321:1440–1444.

    Article  CAS  Google Scholar 

  55. de Pablos-Velasco PL, Pazos Toral F, Esmatjes JE, et al.: Losartan titration versus diuretic combination in type 2 diabetic patients. J Hypertens 2002, 20:715–719.

    Article  PubMed  Google Scholar 

  56. Muirhead N, Feagan BF, Mahon J, et al.: The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999, 60:650–660.

    Article  CAS  Google Scholar 

  57. Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002, 25:95–100.

    Article  PubMed  CAS  Google Scholar 

  58. Rossing K, Christensen PK, Hansen BV, et al.: Optimal dose candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care 2003, 26:150–155. A comparative dose-response trial of the ARB candesartan was studied in patients with type II diabetes with macroalbuminuria.

    Article  PubMed  CAS  Google Scholar 

  59. Segura J, Campo C, Nieto J, et al.: Positive simultaneous effect of candesartan dose up-titration on proteinuria and blood pressure. Am J Hypertens 2003, In press.

  60. Laverman GD, Henning RH, de Jong PE, et al.: Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001, 38:1381–1384.

    PubMed  CAS  Google Scholar 

  61. DROP (Diovan Reduction of Proteinuria) Study. Basel, Switzerland: Novartis Pharmaceuticals; 2003.

  62. SMART (Supramaximal Doses of Atacand and Renal Therapy) Study. Wilmington, DE: AstraZeneca Pharmaceuticals; 2003.

  63. Weinberg MS, Haneiwich R, Weinberg AJ: The safety and efficacy of supramaximal doses of candesartan cilexetil (160 mg) in subjects with a history of hypertension and chronic renal disease that are naive to angiotensin receptor blockade therapy. Am J Hypertens 2003, 16:4A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Clinical Research Center, Rush-Presbyterian-St. Luke’s Medical Center, 1700 W. Van Buren, Suite 470, 60612, Chicago, IL, USA

    George L. Bakris MD

Authors
  1. Marc S. Weinberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas Kaperonis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George L. Bakris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weinberg, M.S., Kaperonis, N. & Bakris, G.L. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?. Current Science Inc 5, 418–425 (2003). https://doi.org/10.1007/s11906-003-0088-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0088-8

Keywords

Search

Navigation